Home>Topics>Stocks>Nektar Therapeutics

Nektar Therapeutics NKTR

  1. All
  2. Commentary
  3. Headlines

    Related Topics:

    1. UPDATE 1-Nektar drug fails late-stage study in breast cancer patients

      Headlines

      Tue, 17 Mar 2015

      March 17 (Reuters) - Nektar Therapeutics said its experimental drug failed to meet the main goal in previously treated patients with advanced breast cancer in a late-stage study.

    2. Nektar drug fails late-stage study in breast cancer patients

      Headlines

      Tue, 17 Mar 2015

      March 17 (Reuters) - Nektar Therapeutics said its experimental drug failed to meet the main goal in previously treated patients with advanced breast cancer in a late-stage study.

    3. BRIEF- Nektar Therapeutics' Phase 3 study of NKTR -102 fails to show significant improvement in overall survival

      Headlines

      Tue, 17 Mar 2015

      * Phase 3 study of NKTR -102 in patients with advanced breast cancer fails to show statistically significant improvement in overall survival

    4. Five Consensus Views that Could Prove Wrong in 2015

      Headlines

      Tue, 27 Jan 2015

      Technosphere insulin has consistently shown signs that it not only improves upon its struggling predecessor ( Pfizer PFE and Nektar's NKTR Exubera), but also that it has the potential to provide better control of glucose levels than the most advanced forms of injectable

    5. Nektar Therapeutics pain drug for knee arthritis fails study

      Headlines

      Thu, 26 Sep 2013

      (Reuters) - Nektar Therapeutics said its experimental drug to treat chronic pain in patients with arthritis of the knee failed to meet its main goal in a mid-stage clinical trial.

    6. Dropping Coverage of Nektar

      Commentary

      Mon, 27 Jul 2009

      We are dropping coverage of Nektar Therapeutics NKTR to focus our resources elsewhere.

    7. Nektar Narrows Loss in 1Q

      Commentary

      Thu, 7 May 2009

      Nektar Therapeutics NKTR reported another quarter of year-over-year revenue decline because of the marketing failure of its inhaled insulin product

    8. Nektar Reports Strong 4Q

      Commentary

      Fri, 20 Mar 2009

      estimate in place after reviewing Nektar Therapeutics ' NKTR fourth-quarter results. Total ..... results from a Phase II study of NKTR -118 in patients with opioid ..... Management has indicated that NKTR -118 will be partnered with another

    9. Nektar Sells Pulmonary Unit

      Commentary

      Tue, 21 Oct 2008

      Nektar Therapeutics NKTR announced today that Novartis NVS will ..... programs, including Amikacin Inhale ( NKTR -061), Ciprofloxacin inhaled powder, and inhaled vancomycin ( NKTR -063). While Nektar wasn't in dire

    10. Nektar's Revenue Drops in 2Q

      Commentary

      Mon, 20 Oct 2008

      After reviewing Nektar's NKTR second-quarter earnings, we are maintaining our fair value estimate. Second-quarter revenue dropped to $40 million from

    « Prev123Next »
    Content Partners